907. Outcomes Research: Plasma Cell Disorders: Poster I

The impact of frailty on real world outcomes for multiple myeloma patients in England – a cohort study from the uncover study group and ukmra frailty group

Utilization and outcome disparities in autologous hematopoietic stem celltransplantation among patients with multiple myeloma in the United States

Real world outcomes for anti CD38 monoclonal antibody naive and exposed patients receiving treatment for multiple myeloma

Integrating the cardiovascular renal metabolic syndrome ckm Construction and validation of a comprehensive model for early identification of high risk multiple myeloma

A prospective pilot study integrating health care coaching into VA hematologic cancer care A VA leukemia lymphoma society LLS collaborative initiative

Real world experience with first line regimens in transplant ineligible patients with multiple myeloma

Comparison of clinical outcomes in multiple myeloma patients treated with chimeric antigen receptor CAR T cell therapy across clinical trials Intention to treat vs per protocol analyses

Real world treatment patterns of elranatamab in patients with multiple myeloma in Japan Findings from the EVEREST study

Systematic review of non icans neurological toxicities associated with BCMA and GPRC5D directed CAR T cell therapy in plasma cell dyscrasia

Updated analysis of survival and treatment evolution in european multiple myeloma patients 2012–2023 across 7 countries from the honeur network

Years of life lost to multiple myeloma remains high A targeted literature review

Impact of maintenance strategies post autologous stem cell transplant in patients with newly diagnosed multiple myeloma and high risk cytogenetic abnormalities

Subcutaneous daratumumab at home is a safe and effective procedure allowing active treatment of frail patients with multiple myeloma

Steroid toxicity in newly diagnosed patients with multiple myeloma treated with a limited dexamethasone regimen Results from the nmsg rest study

Association between extreme heat exposures and survival in patients with multiple myeloma

Chimeric antigen receptor T cells in real world care of multiple myeloma Patient characteristics and healthcare resource utilization

Limited diagnostic utility of abdominal fat pad biopsy for systemic amyloidosis A single institution s experience

What remains matters Real world impact of measurable residual disease testing in multiple myeloma

Bispecific antibodies in real world care of multiple myeloma Patient characteristics and healthcare resource utilization

Characteristics and outcomes of non transplanted newly diagnosed multiple myeloma patients treated with daratumumab bortezomib lenalidomide dexamethasone DVRd with once weekly bortezomib dosing

First line treatment in patients with transplant ineligible newly diagnosed multiple myeloma by age frailty and comorbidity

Real world outcomes of standard and modified daratumumab based therapy in AL amyloidosis A cohort study from a multidisciplinary program in south India

Outcomes for black persons with multiple myeloma A national retrospective trend analysis from 2015 to 2022

Assessing patient reported outcomes in Phase 3 multiple myeloma trials between 2020 2024 – a systematic review

Quality of life in multiple myeloma A scoping review

Unstructured serum electrophoresis data limits real world AI models in multiple myeloma Evaluation of 384 institutions across United States

Race agnostic models maintain accuracy in predicting m protein levels in multiple myeloma

Impact of race and socioeconomics on access to T cell engaging therapy in US patients with relapsed refractory multiple myeloma RRMM

Infection risk factors and burden in patients treated with T cell engaging bispecific antibodies for relapsed B cell lymphoma and multiple myeloma

Who participates in myeloma trials clinical and geographic predictors of access and outcomes in British Columbia Canada

No CARs for miles Geographic disparities in access to multiple myeloma CAR T therapy

Real world patient characteristics treatment patterns and outcomes among relapsed refractory multiple myeloma patients receiving talquetamab tgvs